Dr. Carter, a Professor in the Section of Molecular Hematology and Therapy, Department of Leukemia has 20+ years of experience in molecular biology, biochemistry, and leukemia research. Her research focuses on understanding the mechanisms of drug resistance and targeting anti-apoptotic proteins and cell survival signaling pathways in myeloid leukemia. She is developing mechanism-based combinational strategies in therapy-resistant AML to overcome drug resistance and eradicate myeloid leukemia cells and leukemia stem/progenitor cells. She has published extensively in the field and several clinical trials have been developed based on her pre-clinical studies. Her recent works demonstrated the effectiveness and mechanisms of action of combined inhibition of antiapoptotic proteins Bcl-2 and Mcl-1 using BH3 mimetics (Blood Cancer Journal, 2023) and targeting HSP90 epichaperomes (Blood, 2023) in TP53 mutant AML.